Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: Estrogen receptor dependent or independent pathways of raloxifene

Journal of Steroid Biochemistry and Molecular Biology

Volumn 113, Issue 3-5, 2009, Pages 281-289

  Miki, Yasuhiro ^a   Suzuki, Takashi ^a   Nagasaki, Shuji ^a   Hata, Shuko ^a   Akahira, Jun ichi ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Estrogen; Osteoblasts; Osteoporosis; SERM

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; GROWTH ARREST SPECIFIC PROTEIN 6; RALOXIFENE; TAMOXIFEN; TRANSCRIPTION FACTOR MAF;

ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OSTEOBLAST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

CELL CYCLE; CELL LINE; CELL PROLIFERATION; CLUSTER ANALYSIS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; RALOXIFENE; REPRODUCIBILITY OF RESULTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 61349111321     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.01.010     Document Type: Article

References (47)

1. Riggs B.L., Khosla S., and Melton III L.J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13 (1998) 763-773
2. Turner R.T., Wakley G.K., Hannon K.S., and Bell N.H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122 (1988) 1146-1150
3. Takano-Yamamoto T., and Rodan G.A. Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 2172-2176
4. Huang W.H., Lau A.T., Daniels L.L., Fujii H., Seydel U., Wood D.J., Papadimitriou J.M., and Zheng M.H. Detection of estrogen receptor alpha, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNAs in putative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in situ hybridization. J. Mol. Endocrinol. 20 (1998) 211-219
5. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., and Ohlsson C. Androgens and bone. Endocr. Rev. 25 (2004) 389-425
6. Vidal O., Kindblom L.G., and Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone. J. Bone Miner. Res. 14 (1999) 923-929
7. Bord S., Horner A., Beavan S., and Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86 (2001) 2309-2314
8. Bland R. Steroid hormone receptor expression and action in bone. Clin. Sci. (Lond). 98 (2000) 217-240
9. Felson D.T., Zhang Y., Hannan M.T., Kiel D.P., Wilson P.W., and Anderson J.J. The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329 (1993) 1141-1146
10. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., and Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85 (1995) 304-313
11. Beresford S.A., Weiss N.S., Voigt L.F., and McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 (1997) 458-461
12. Sato M., McClintock C., Kim J., Turner C.H., Bryant H.U., Magee D., and Slemenda C.W. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J. Bone Miner. Res. 9 (1994) 715-724
13. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., and Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (1997) 1641-1647
14. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., and Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282 (1999) 637-645
15. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon III J.L., Wadem, Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., and Wolmark N. National surgical adjuvant breast and bowel project (NSABP), Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (2006) 2727-2741
16. Bryant H.U., Glasebrook A.L., Yang N.N., and Sato M. An estrogen receptor basis for raloxifene action in bone. J. Steroid Biochem. Mol. Biol. 69 (1999) 37-44
17. Fournier B., Haring S., Kaye A.M., and Somjen D. Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J. Endocrinol. 150 (1996) 275-285
18. Qu Q., Harkonen P.L., and Vaananen H.K. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J. Cell Biochem. 73 (1999) 500-507
19. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., Agnusdei D., Termine J.D., and Migliaccio S. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 (2002) 368-376
20. Jordan V.C. Effects of tamoxifen in relation to breast cancer. Br. Med. J. 1 (1977) 1534-1535
21. Swaby R.F., Sharma C.G., and Jordan V.C. SERMs for the treatment and prevention of breast cancer. Rev. Endocr. Metab. Disord. 8 (2007) 229-239
22. Barrett-Connor E. Raloxifene: risks and benefits. Ann. N.Y. Acad. Sci. 949 (2001) 295-303
23. Kian T.M., Rogatsky I., Tzagarakis-Foster C., Cvoro A., An J., Christy R.J., Yamamoto K.R., and Leitman D.C. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol. Biol. Cell 15 (2004) 1262-1272
24. Harris S.A., Enger R.J., Riggs B.L., and Spelsberg T.C. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J. Bone Miner. Res. 10 (1995) 178-186
25. Miki Y., Suzuki T., Hatori M., Igarashi K., Aisaki K., Kanno J., Nakamura Y., Uzuki M., Sawai T., and Sasano H. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone 40 (2007) 876-887
26. Miki Y., Suzuki T., Tazawa C., Ishizuka M., Semba S., Gorai I., and Sasano H. Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mülerian duct cells using microarray. Cancer Lett. 220 (2005) 197-210
27. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 14863-14868
28. Tou L., Quibria N., and Alexander J.M. Regulation of human cbfa1 gene transcription in osteoblasts by selective estrogen receptor modulators (SERMs). Mol. Cell Endocrinol. 183 (2001) 71-79
29. Schultz J.R., Petz L.N., and Nardulli A.M. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J. Biol. Chem. 280 (2005) 347-354
30. Cheung J., Mak Y.T., Papaioannou S., Evans B.A., Fogelman I., and Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J. Endocrinol. 177 (2003) 423-433
31. Mendez-Davila C., Garcia-Moreno C., Turbi C., and de la Piedra C. Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures. J. Endocrinol. Invest. 27 (2004) 904-912
32. Cao S., Liu J., Chesi M., Bergsagel P.L., Ho I.C., Donnelly R.P., and Ma X. Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J. Immunol. 169 (2002) 5715-5725
33. Rodan G.A., Raisz L.G., and Bilezikian J.P. Pathophysiology of osteoporosis (chapter 73). In: Bilezikian J.P., Raisz L.G., and Rodan A. (Eds). Principles of Bone Biology. 2nd ed. vol. 1 (2002), Academic Press, A Division of Harcourt, Inc., NY, USA 1275-1290
34. MacLean H.E., Kim J.I., Glimcher M.J., Wang J., Kronenberg H.M., and Glimcher L.H. Absence of transcription factor c-maf causes abnormal terminal differentiation of hypertrophic chondrocytes during endochondral bone development. Dev. Biol. 262 (2003) 51-63
35. Kienast J., and Berdel W.E. c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions. Cancer Cell 5 (2004) 109-110
36. Kawaguchi H., Katagiri M., and Chikazu D. Osteoclastic bone resorption through receptor tyrosine kinase and extracellular signal-regulated kinase signaling in mature osteoclasts. Mod. Rheumatol. 14 (2004) 1-5
37. Goruppi S., Ruaro E., and Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12 (1996) 471-480
38. Bourdeau V., Deschenes J., Metivier R., Nagai Y., Nguyen D., Bretschneider N., Gannon F., White J.H., and Mader S. Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol. Endocrinol. 18 (2004) 1411-1427
39. Mo R.T., Zhu Y., Zhang Z., Rao S.M., and Zhu Y.J. GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochem. Biophys. Res. Commun. 353 (2007) 189-194
40. Cook S.A., Matsui T., Li L., and Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J. Biol. Chem. 277 (2002) 22528-22533
41. Conn K.J., Ullman M.D., Eisenhauer P.B., Fine R.E., and Wells J.M. Decreased expression of the NADH:ubiquinone oxidoreductase (complex I) subunit 4 in 1-methyl-4-phenylpyridinium-treated human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 306 (2001) 145-148
42. Dubey R.K., and Jackson E.K. Cardiovascular protective effects of 17beta-estradiol metabolites. J. Appl. Physiol. 91 (2001) 1868-1883
43. Maran A., Zhang M., Kennedy A.M., and Turner R.T. ER-independent actions of estrogen and estrogen metabolites in bone cells. J. Musculoskelet. Neuronal. Interact. 3 (2003) 367-369
44. Desai P.B., Nallani S.C., Sane R.S., Moore L.B., Goodwin B.J., Buckley D.J., and Buckley A.R. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos. 30 (2002) 608-612
45. Ichikawa T., Horie-Inoue K., Ikeda K., Blumberg B., and Inoue S. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J. Biol. Chem. 281 (2006) 16927-16934
46. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21 (2000) 115-137
47. Michael H., Harkonen P.L., Kangas L., Vaananen H.K., and Hentunen T.A. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br. J. Pharmacol. 151 (2007) 384-395